Recent developments in antiandrogens and selective androgen receptor modulators

Molecular and Cellular Endocrinology

Volumn 352, Issue 1-2, 2012, Pages 79-91

  Haendler, Bernard ^a   Cleve, Arwed ^a  

^a Global Drug Discovery   (Germany)

Author keywords

Androgen receptor; Antiandrogen; Cachexia; Prostate cancer; SARM

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ANDROGEN; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANTIANDROGEN; ARYL PROPIONAMIDE; BICALUTAMIDE; BMS 641988; BMS 779333; CALUSTERONE; CH 5137291; CH5137291; CLOMIFENE CITRATE; CYPROTERONE ACETATE; EPI 001; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; MK 0773; NILUTAMIDE; NUCLEAR RECEPTOR COACTIVATOR 2; OXINDOLE; OXINDOLE I; PYGEUM AFRICANUM EXTRACT; RD 162; RD162; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SINTOKAMIDE A; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ANDROGEN THERAPY; BREAST CANCER; CACHEXIA; CANCER RESISTANCE; DRUG DEVELOPMENT; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; FATIGUE; FRAILTY SYNDROME; HUMAN; KENNEDY DISEASE; MOLECULAR PATHOLOGY; MUSCULOSKELETAL DISEASE; NONHUMAN; OVARY POLYCYSTIC DISEASE; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN ANALYSIS; PROTEIN INTERACTION; REVIEW; SEIZURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER;

ANDROGEN ANTAGONISTS; DIHYDROTESTOSTERONE; DRUG DISCOVERY; GONADAL DISORDERS; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84857362154     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.06.002     Document Type: Review

References (199)

1. Ahrens-Fath I., Politz O., Geserick C., Haendler B. Androgen receptor function is modulated by the tissue-specific AR45 variant. FEBS J. 2005, 272:74-84.
2. Akaza H. Effectiveness of Maximal Androgen Blockade (MAB): illusion or reality?. Can. J. Urol. 2005, 12(Suppl. 1):77-80.
3. Akaza H. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness. Cancer Sci. 2011, 102:51-56.
4. Allan G.F., Tannenbaum P., Sbriscia T., Linton O., Lai M.T., Haynes-Johnson D., Bhattacharjee S., Zhang X., Sui Z., Lundeen S.G. A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats. Endocrine 2007, 32:41-51.
5. Andersen R.J., Mawji N.R., Wang J., Wang G., Haile S., Myung J.K., Watt K., Tam T., Yang Y.C., Banuelos C.A., et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010, 17:535-546.
6. Aoyagi S., Trotter K.W., Archer T.K. ATP-dependent chromatin remodeling complexes and their role in nuclear receptor-dependent transcription in vivo. Vitam. Horm. 2005, 70:281-307.
7. Artini P.G., Di Berardino O.M., Simi G., Papini F., Ruggiero M., Monteleone P., Cela V. Best methods for identification and treatment of PCOS. Minerva Ginecol. 2010, 62:33-48.
8. Aspinall S.R., Stamp S., Davison A., Shenton B.K., Lennard T.W. The proliferative effects of 5-androstene-3 beta, 17 beta-diol and 5 alpha-dihydrotestosterone on cell cycle analysis and cell proliferation in MCF7, T47D and MDAMB231 breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 2004, 88:37-51.
9. Attar R.M., Jure-Kunkel M., Balog A., Cvijic M.E., Dell-John J., Rizzo C.A., Schweizer L., Spires T.E., Platero J.S., Obermeier M., et al. Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer. Cancer Res. 2009, 69:6522-6530.
10. Bachelot A., Chabbert-Buffet N., Salenave S., Kerlan V., Galand-Portier M.B. Anti-androgen treatments. Ann. Endocrinol. (Paris) 2010, 71:19-24.
11. Baek S.H., Ohgi K.A., Nelson C.A., Welsbie D., Chen C., Sawyers C.L., Rose D.W., Rosenfeld M.G. Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proc. Natl. Acad. Sci. USA 2006, 103:3100-3105.
12. Banno H., Katsuno M., Suzuki K., Takeuchi Y., Kawashima M., Suga N., Takamori M., Ito M., Nakamura T., Matsuo K., et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann. Neurol. 2009, 65:140-150.
13. Barmoshe S., Zlotta A.R. Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments. Expert Opin. Pharmacother. 2006, 7:1685-1699.
14. Barradell L.B., Faulds D. Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer. Drugs Aging 1994, 5:59-80.
15. Basaria S., Dobs A.S. Risks versus benefits of testosterone therapy in elderly men. Drugs Aging 1999, 15:131-142.
16. Bassil N., Morley J.E. Late-life onset hypogonadism: a review. Clin. Geriatr. Med. 2010, 26:197-222.
17. Bauer P.O., Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J. Neurochem. 2009, 110:1737-1765.
18. Beardsley E.K., Chi K.N. Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer. Curr. Opin. Support. Palliat. Care 2008, 2:161-166.
19. Bergerat J.P., Ceraline J. Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Hum. Mutat. 2009, 30:145-157.
20. Berry P.A., Maitland N.J., Collins A.T. Androgen receptor signalling in prostate: effects of stromal factors on normal and cancer stem cells. Mol. Cell. Endocrinol. 2008, 288:30-37.
21. Bhasin S., Cunningham G.R., Hayes F.J., Matsumoto A.M., Snyder P.J., Swerdloff R.S., Montori V.M. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2010, 95:2536-2559.
22. Bhasin S., Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr. Opin. Clin. Nutr. Metab. Care 2009, 12:232-240.
23. Bohl C.E., Gao W., Miller D.D., Bell C.E., Dalton J.T. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl. Acad. Sci. USA 2005, 102:6201-6206.
24. Bohl C.E., Wu Z., Miller D.D., Bell C.E., Dalton J.T. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J. Biol. Chem. 2007, 282:13648-13655.
25. Bolton E.C., So A.Y., Chaivorapol C., Haqq C.M., Li H., Yamamoto K.R. Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev. 2007, 21:2005-2017.
26. Brinkmann A.O., Faber P.W., van Rooij H.C., Kuiper G.G., Ris C., Klaassen P., van der Korput J.A., Voorhorst M.M., van Laar J.H., Mulder E., et al. The human androgen receptor: domain structure, genomic organization and regulation of expression. J. Steroid Biochem. 1989, 34:307-310.
27. Brodkin R.A., Cooper M.R. Calusterone. Ann. Intern. Med. 1978, 89:945-948.
28. Brogden R.N., Chrisp P. Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer. Drugs Aging 1991, 1:104-115.
29. Brooke G.N., Bevan C.L. The role of androgen receptor mutations in prostate cancer progression. Curr. Genomics 2009, 10:18-25.
30. Callewaert L., Verrijdt G., Christiaens V., Haelens A., Claessens F. Dual function of an amino-terminal amphipatic helix in androgen receptor-mediated transactivation through specific and nonspecific response elements. J. Biol. Chem. 2003, 278:8212-8218.
31. Calof O.M., Singh A.B., Lee M.L., Kenny A.M., Urban R.J., Tenover J.L., Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J. Gerontol. A. Biol. Sci. Med. Sci. 2005, 60:1451-1457.
32. Carnevale V., Romagnoli E., Cipriani C., Del Fiacco R., Piemonte S., Pepe J., Scillitani A., Minisola S. Sex hormones and bone health in males. Arch. Biochem. Biophys. 2010, 503:110-117.
33. Cauley J.A., Lucas F.L., Kuller L.H., Stone K., Browner W., Cummings S.R. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann. Intern. Med. 1999, 130:270-277.
34. Chang C., Saltzman A., Yeh S., Young W., Keller E., Lee H.J., Wang C., Mizokami A. Androgen receptor: an overview. Crit. Rev. Eukaryot. Gene Expr. 1995, 5:97-125.
35. Chang C.S., Kokontis J., Liao S.T. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988, 240:324-326.
36. Chang C.Y., McDonnell D.P. Androgen receptor-cofactor interactions as targets for new drug discovery. Trends Pharmacol. Sci. 2005, 26:225-228.
37. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10:33-39.
38. Chen Y., Sawyers C.L., Scher H.I. Targeting the androgen receptor pathway in prostate cancer. Curr. Opin. Pharmacol. 2008, 8:440-448.
39. Chenoweth D.M., Harki D.A., Phillips J.W., Dose C., Dervan P.B. Cyclic pyrrole-imidazole polyamides targeted to the androgen response element. J. Am. Chem. Soc. 2009, 131:7182-7188.
40. Claessens F., Denayer S., Van Tilborgh N., Kerkhofs S., Helsen C., Haelens A. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl. Recept. Signal. 2008, 6:e008.
41. Cockshott I.D. Bicalutamide: clinical pharmacokinetics and metabolism. Clin. Pharmacokinet. 2004, 43:855-878.
42. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65:10946-10951.
43. Coss C.C., Bohl C.E., Dalton J.T. Cancer cachexia therapy: a key weapon in the fight against cancer. Curr. Opin. Clin. Nutr. Metab. Care 2011, 14:268-273.
44. Culig Z., Bartsch G. Androgen axis in prostate cancer. J. Cell. Biochem. 2006, 99:373-381.
45. Culig Z., Bartsch G., Hobisch A. Antiandrogens in prostate cancer endocrine therapy. Curr. Cancer Drug Targets 2004, 4:455-461.
46. Dankbar B., Brinkworth M.H., Schlatt S., Weinbauer G.F., Nieschlag E., Gromoll J. Ubiquitous expression of the androgen receptor and testis-specific expression of the FSH receptor in the cynomolgus monkey (Macaca fascicularis) revealed by a ribonuclease protection assay. J. Steroid Biochem. Mol. Biol. 1995, 55:35-41.
47. Dayger C., Villasana L., Pfankuch T., Davis M., Raber J. Effects of the SARM ACP-105 on rotorod performance and cued fear conditioning in sham-irradiated and irradiated female mice. Brain Res. 2011, 1381:134-140.
48. Dehm S.M., Tindall D.J. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol. Endocrinol. 2007, 21:2855-2863.
49. Denayer S., Helsen C., Thorrez L., Haelens A., Claessens F. The rules of DNA recognition by the androgen receptor. Mol. Endocrinol. 2010, 24:898-913.
50. Denmeade S.R., Isaacs J.T. A history of prostate cancer treatment. Nat. Rev. Cancer 2002, 2:389-396.
51. Dimitrakakis C., Bondy C. Androgens and the breast. Breast Cancer Res. 2009, 11:212.
52. Dole E.J., Holdsworth M.T. Nilutamide: an antiandrogen for the treatment of prostate cancer. Ann. Pharmacother. 1997, 31:65-75.
53. Donkena K.V., Yuan H., Young C.Y. Recent advances in understanding hormonal therapy resistant prostate cancer. Curr. Cancer Drug Targets 2010, 10:402-410.
54. Dubbink H.J., Hersmus R., Verma C.S., van der Korput H.A., Berrevoets C.A., van Tol J., Ziel-van der Made A.C., Brinkmann A.O., Pike A.C., Trapman J. Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor. Mol. Endocrinol. 2004, 18:2132-2150.
55. Edelstein D., Basaria S. Testosterone undecanoate in the treatment of male hypogonadism. Expert Opin. Pharmacother. 2010, 11:2095-2106.
56. Engel J.B., Schally A.V. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3:157-167.
57. Estebanez-Perpina E., Arnold L.A., Nguyen P., Rodrigues E.D., Mar E., Bateman R., Pallai P., Shokat K.M., Baxter J.D., Guy R.K., et al. A surface on the androgen receptor that allosterically regulates coactivator binding. Proc. Natl. Acad. Sci. USA 2007, 104:16074-16079.
58. Estebanez-Perpina E., Moore J.M., Mar E., Delgado-Rodrigues E., Nguyen P., Baxter J.D., Buehrer B.M., Webb P., Fletterick R.J., Guy R.K. The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J. Biol. Chem. 2005, 280:8060-8068.
59. Evans W.J., Morley J.E., Argiles J., Bales C., Baracos V., Guttridge D., Jatoi A., Kalantar-Zadeh K., Lochs H., Mantovani G., et al. Cachexia: a new definition. Clin. Nutr. 2008, 27:793-799.
60. Faus H., Haendler B. Post-translational modifications of steroid receptors. Biomed. Pharmacother. 2006, 60:520-528.
61. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001, 1:34-45.
62. Fischbeck K.H., Bryan W.W. Anti-androgen treatment for spinal and bulbar muscular atrophy. Ann. Neurol. 2009, 65:119-120.
63. Foster W.R., Car B.D., Shi H., Levesque P.C., Obermeier M.T., Gan J., Arezzo J.C., Powlin S.S., Dinchuk J.E., Balog A., et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 2011, 71:480-488.
64. Gao W., Dalton J.T. Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase?. Mol. Interv. 2007, 7:10-13.
65. Gao W., Reiser P.J., Coss C.C., Phelps M.A., Kearbey J.D., Miller D.D., Dalton J.T. Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 2005, 146:4887-4897.
66. Gerace E., Salomone A., Fasano F., Costa R., Boschi D., Di Stilo A., Vincenti M. Validation of a GC/MS method for the detection of two quinolinone-derived selective androgen receptor modulators in doping control analysis. Anal. Bioanal. Chem. 2011, 400:137-144.
67. Geserick C., Meyer H.A., Barbulescu K., Haendler B. Differential modulation of androgen receptor action by deoxyribonucleic acid response elements. Mol. Endocrinol. 2003, 17:1738-1750.
68. Geserick C., Meyer H.A., Haendler B. The role of DNA response elements as allosteric modulators of steroid receptor function. Mol. Cell. Endocrinol. 2005, 236:1-7.
69. Glass D., Roubenoff R. Recent advances in the biology and therapy of muscle wasting. Ann. NY Acad. Sci. 2010, 1211:25-36.
70. Gnanapragasam V.J., Robson C.N., Leung H.Y., Neal D.E. Androgen receptor signalling in the prostate. BJU Int. 2000, 86:1001-1013.
71. Goldenberg I.S. Testosterone propionate therapy in breast cancer. JAMA 1964, 188:1069-1072.
72. Gucalp A., Traina T.A. Triple-negative breast cancer: role of the androgen receptor. Cancer J. 2010, 16:62-65.
73. Gunther J.R., Parent A.A., Katzenellenbogen J.A. Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors. ACS Chem. Biol. 2009, 4:435-440.
74. Habenicht U.F., Schroder H., el Etreby M.F., Neumann F. Advantages and disadvantages of pure antiandrogens and of antiandrogens of the cyproterone acetate-type in the treatment of prostatic cancer. Prog. Clin. Biol. Res. 1988, 260:63-75.
75. Hamann L.G., Higuchi R.I., Zhi L., Edwards J.P., Wang X.N., Marschke K.B., Kong J.W., Farmer L.J., Jones T.K. Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines. J. Med. Chem. 1998, 41:623-639.
76. Hanada K., Furuya K., Yamamoto N., Nejishima H., Ichikawa K., Nakamura T., Miyakawa M., Amano S., Sumita Y., Oguro N. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol. Pharm. Bull. 2003, 26:1563-1569.
77. He B., Gampe R.T., Kole A.J., Hnat A.T., Stanley T.B., An G., Stewart E.L., Kalman R.I., Minges J.T., Wilson E.M. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol. Cell 2004, 16:425-438.
78. 2-terminal interaction with the ligand binding domain of the androgen receptor. J. Biol. Chem. 2000, 275:22986-22994.
79. He H.H., Meyer C.A., Shin H., Bailey S.T., Wei G., Wang Q., Zhang Y., Xu K., Ni M., Lupien M., et al. Nucleosome dynamics define transcriptional enhancers. Nat. Genet. 2010, 42:343-347.
80. Heemers H.V., Tindall D.J. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 2007, 28:778-808.
81. Heinlein C.A., Chang C. Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 2002, 23:175-200.
82. Holzbeierlein J., Lal P., LaTulippe E., Smith A., Satagopan J., Zhang L., Ryan C., Smith S., Scher H., Scardino P., et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 2004, 164:217-227.
83. Hughes I.A., Lim H.N., Martin H., Mongan N.P., Dovey L., Ahmed S.F., Hawkins J.R. Developmental aspects of androgen action. Mol. Cell. Endocrinol. 2001, 185:33-41.
84. Huhtaniemi I., Forti G. Male late-onset hypogonadism: pathogenesis, diagnosis and treatment. Nat. Rev. Urol. 2011, 8:335-344.
85. Ingle J.N., Suman V.J., Mailliard J.A., Kugler J.W., Krook J.E., Michalak J.C., Pisansky T.M., Wold L.E., Donohue J.H., Goetz M.P., Perez E.A. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res. Treat. 2006, 98:217-222.
86. Jenster G., van der Korput H.A., Trapman J., Brinkmann A.O. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J. Biol. Chem. 1995, 270:7341-7346.
87. Jiang Y., Palma J.F., Agus D.B., Wang Y., Gross M.E. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin. Chem. 2010, 56:1492-1495.
88. Jones J.O., An W.F., Diamond M.I. AR inhibitors identified by high-throughput microscopy detection of conformational change and subcellular localization. ACS Chem. Biol. 2009, 4:199-208.
89. Jones J.O., Bolton E.C., Huang Y., Feau C., Guy R.K., Yamamoto K.R., Hann B., Diamond M.I. Non-competitive androgen receptor inhibition in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2009, 106:7233-7238.
90. Joseph J.D., Wittmann B.M., Dwyer M.A., Cui H., Dye D.A., McDonnell D.P., Norris J.D. Inhibition of prostate cancer cell growth by second-site androgen receptor antagonists. Proc. Natl. Acad. Sci. USA 2009, 106:12178-12183.
91. Jung M.E., Ouk S., Yoo D., Sawyers C.L., Chen C., Tran C., Wongvipat J. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J. Med. Chem. 2010, 53:2779-2796.
92. Kang Z., Janne O.A., Palvimo J.J. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol. Endocrinol. 2004, 18:2633-2648.
93. Katsuno M., Adachi H., Doyu M., Minamiyama M., Sang C., Kobayashi Y., Inukai A., Sobue G. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat. Med. 2003, 9:768-773.
94. Katzenellenbogen J.A., O'Malley B.W., Katzenellenbogen B.S. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol. Endocrinol. 1996, 10:119-131.
95. Kazi M., Geraci S.A., Koch C.A. Considerations for the diagnosis and treatment of testosterone deficiency in elderly men. Am. J. Med. 2007, 120:835-840.
96. Kearbey J.D., Gao W., Narayanan R., Fisher S.J., Wu D., Miller D.D., Dalton J.T. Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm. Res. 2007, 24:328-335.
97. Kicman A.T. Pharmacology of anabolic steroids. Br. J. Pharmacol. 2008, 154:502-521.
98. Kilbourne E.J., Moore W.J., Freedman L.P., Nagpal S. Selective androgen receptor modulators for frailty and osteoporosis. Curr. Opin. Investig. Drugs 2007, 8:821-829.
99. Kinoyama I., Taniguchi N., Kawaminami E., Nozawa E., Koutoku H., Furutani T., Kudoh M., Okada M. N-Arylpiperazine-1-carboxamide derivatives: a novel series of orally active nonsteroidal androgen receptor antagonists. Chem. Pharm. Bull. (Tokyo) 2005, 53:402-409.
100. Kinoyama I., Taniguchi N., Toyoshima A., Nozawa E., Kamikubo T., Imamura M., Matsuhisa A., Samizu K., Kawanimani E., Niimi T., et al. (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist. J. Med. Chem. 2006, 49:716-726.
101. Klotz L. Maximal androgen blockade for advanced prostate cancer. Best Pract. Res. Clin. Endocrinol. Metab. 2008, 22:331-340.
102. Klotz L., Schellhammer P. Combined androgen blockade: the case for bicalutamide. Clin. Prostate Cancer 2005, 3:215-219.
103. Knudsen K.E., Penning T.M. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol. Metab. 2010, 21:315-324.
104. Koochekpour S. Androgen receptor signaling and mutations in prostate cancer. Asian J. Androl. 2010, 12:639-657.
105. Kudwa A.E., Lopez F.J., McGivern R.F., Handa R.J. A selective androgen receptor modulator enhances male-directed sexual preference, proceptive behavior, and lordosis behavior in sexually experienced, but not sexually naive, female rats. Endocrinology 2010, 151:2659-2668.
106. Labrie F. Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat. Rev. Urol. 2011, 8:73-85.
107. Lanter J.C., Fiordeliso J.J., Jiang W., Allan G.F., Lai M.T., Linton O., Hahn do W., Lundeen S.G., Sui Z. The discovery of a potent orally efficacious indole androgen receptor antagonist through in vivo screening. Bioorg. Med. Chem. Lett. 2007, 17:123-126.
108. Li J., Al-Azzawi F. Mechanism of androgen receptor action. Maturitas 2009, 63:142-148.
109. Lin F.M., Tsai C.H., Yang Y.C., Tu W.C., Chen L.R., Liang Y.S., Wang S.Y., Shyur L.F., Chien S.C., Cha T.L., Hsiao P.W. A novel diterpene suppresses CWR22Rv1 tumor growth in vivo through antiproliferation and proapoptosis. Cancer Res. 2008, 68:6634-6642.
110. Lin H.Y., Sun M., Lin C., Tang H.Y., London D., Shih A., Davis F.B., Davis P.J. Androgen-induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells. J. Steroid Biochem. Mol. Biol. 2009, 113:182-188.
111. Linja M.J., Visakorpi T. Alterations of androgen receptor in prostate cancer. J. Steroid Biochem. Mol. Biol. 2004, 92:255-264.
112. Lubahn D.B., Joseph D.R., Sullivan P.M., Willard H.F., French F.S., Wilson E.M. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 1988, 240:327-330.
113. Luo X., Shi Y.X., Li Z.M., Jiang W.Q. Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin. J. Cancer 2010, 29:585-590.
114. Mahler C., Verhelst J., Denis L. Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. Clin. Pharmacokinet. 1998, 34:405-417.
115. Maitland N.J., Collins A.T. Prostate cancer stem cells: a new target for therapy. J. Clin. Oncol. 2008, 26:2862-2870.
116. Makkonen H., Kauhanen M., Jaaskelainen T., Palvimo J.J. Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells. Mol. Cell. Endocrinol. 2011, 331:57-65.
117. Marques R.B., Dits N.F., Erkens-Schulze S., van Weerden W.M., Jenster G. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS One 2010, 5:e13500.
118. Martinborough E., Shen Y., Oeveren A., Long Y.O., Lau T.L., Marschke K.B., Chang W.Y., Lopez F.J., Vajda E.G., Rix P.J., et al. Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators. J. Med. Chem. 2007, 50:5049-5052.
119. Maruyama K., Noguchi-Yachide T., Sugita K., Hashimoto Y., Ishikawa M. Novel selective anti-androgens with a diphenylpentane skeleton. Bioorg. Med. Chem. Lett. 2010, 20:6661-6666.
120. Matias P.M., Donner P., Coelho R., Thomaz M., Peixoto C., Macedo S., Otto N., Joschko S., Scholz P., Wegg A., et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J. Biol. Chem. 2000, 275:26164-26171.
121. Matsumoto T., Shiina H., Kawano H., Sato T., Kato S. Androgen receptor functions in male and female physiology. J. Steroid. Biochem. Mol. Biol. 2008, 109:236-241.
122. McEwan I.J. Molecular mechanisms of androgen receptor-mediated gene regulation: structure-function analysis of the AF-1 domain. Endocr. Relat. Cancer 2004, 11:281-293.
123. McLeod D.G., Iversen P., See W.A., Morris T., Armstrong J., Wirth M.P. Bicalutamide 150mg plus standard care vs standard care alone for early prostate cancer. BJU Int. 2006, 97:247-254.
124. Meijsing S.H., Pufall M.A., So A.Y., Bates D.L., Chen L., Yamamoto K.R. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 2009, 324:407-410.
125. Miyamoto H., Rahman M.M., Chang C. Molecular basis for the antiandrogen withdrawal syndrome. J. Cell. Biochem. 2004, 91:3-12.
126. Moehren U., Eckey M., Baniahmad A. Gene repression by nuclear hormone receptors. Essays Biochem. 2004, 40:89-104.
127. Mohler J.L., Titus M.A., Bai S., Kennerley B.J., Lih F.B., Tomer K.B., Wilson E.M. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res. 2011, 71:1486-1496.
128. Mohler M.L., Bohl C.E., Jones A., Coss C.C., Narayanan R., He Y., Hwang D.J., Dalton J.T., Miller D.D. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J. Med. Chem. 2009, 52:3597-3617.
129. Monks D.A., Rao P., Mo K., Johansen J.A., Lewis G., Kemp M.Q. Androgen receptor and Kennedy disease/spinal bulbar muscular atrophy. Horm. Behav. 2008, 53:729-740.
130. Montgomery R.B., Mostaghel E.A., Vessella R., Hess D.L., Kalhorn T.F., Higano C.S., True L.D., Nelson P.S. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008, 68:4447-4454.
131. Moore T.W., Mayne C.G., Katzenellenbogen J.A. Minireview: not picking pockets: nuclear receptor alternate-site modulators (NRAMs). Mol. Endocrinol. 2010, 24:683-695.
132. Morgan T.M., Koreckij T.D., Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr. Cancer Drug Targets 2009, 9:237-249.
133. Mukherjee A., Kirkovsky L., Yao X.T., Yates R.C., Miller D.D., Dalton J.T. Enantioselective binding of Casodex to the androgen receptor. Xenobiotica 1996, 26:117-122.
134. Narayanan R., Coss C.C., Yepuru M., Kearbey J.D., Miller D.D., Dalton J.T. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol. Endocrinol. 2008, 22:2448-2465.
135. Narayanan R., Mohler M.L., Bohl C.E., Miller D.D., Dalton J.T. Selective androgen receptor modulators in preclinical and clinical development. Nucl. Recept. Signal. 2008, 6:e010.
136. Neumann F. The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp. Clin. Endocrinol. 1994, 102:1-32.
137. Ng R.A., Guan J., Alford V.C., Lanter J.C., Allan G.F., Sbriscia T., Lundeen S.G., Sui Z. 2-(2,2,2-Trifluoroethyl)-5,6-dichlorobenzimidazole derivatives as potent androgen receptor antagonists. Bioorg. Med. Chem. Lett. 2007, 17:955-958.
138. Nickols N.G., Dervan P.B. Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide. Proc. Natl. Acad. Sci. USA 2007, 104:10418-10423.
139. Nicolas Diaz-Chico B., German Rodriguez F., Gonzalez A., Ramirez R., Bilbao C., Cabrera de Leon A., Aguirre Jaime A., Chirino R., Navarro D., Diaz-Chico J.C. Androgens and androgen receptors in breast cancer. J. Steroid Biochem. Mol. Biol. 2007, 105:1-15.
140. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin. Endocrinol. (Oxf) 2006, 65:275-281.
141. Nishiyama T., Ishizaki F., Anraku T., Shimura H., Takahashi K. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J. Clin. Endocrinol. Metab. 2005, 90:657-660.
142. Orr C.R., Montie H.L., Liu Y., Bolzoni E., Jenkins S.C., Wilson E.M., Joseph J.D., McDonnell D.P., Merry D.E. An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. J. Biol. Chem. 2010, 285:35567-35577.
143. Ostrowski J., Kuhns J.E., Lupisella J.A., Manfredi M.C., Beehler B.C., Krystek S.R., Bi Y., Sun C., Seethala R., Golla R., et al. Pharmacological and X-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology 2007, 148:4-12.
144. Pal S.K., Sartor O. Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. Maturitas 2011, 68:103-105.
145. Palazzolo I., Gliozzi A., Rusmini P., Sau D., Crippa V., Simonini F., Onesto E., Bolzoni E., Poletti A. The role of the polyglutamine tract in androgen receptor. J. Steroid Biochem. Mol. Biol. 2008, 108:245-253.
146. Penna F., Minero V.G., Costamagna D., Bonelli G., Baccino F.M., Costelli P. Anti-cytokine strategies for the treatment of cancer-related anorexia and cachexia. Expert Opin. Biol. Ther. 2010, 10:1241-1250.
147. Pereira de Jesus-Tran K., Cote P.L., Cantin L., Blanchet J., Labrie F., Breton R. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci. 2006, 15:987-999.
148. Perez-Lopez F.R., Larrad-Mur L., Kallen A., Chedraui P., Taylor H.S. Gender differences in cardiovascular disease: hormonal and biochemical influences. Reprod. Sci. 2010, 17:511-531.
149. Petrylak D.P. Current clinical trials in castrate-resistant prostate cancer. Curr. Urol. Rep. 2011, 12:173-179.
150. Piu F., Gardell L.R., Son T., Schlienger N., Lund B.W., Schiffer H.H., Vanover K.E., Davis R.E., Olsson R., Bradley S.R. Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator. J. Steroid Biochem. Mol. Biol. 2008, 109:129-137.
151. Prescott J., Jariwala U., Jia L., Cogan J.P., Barski A., Pregizer S., Shen H.C., Arasheben A., Neilson J.J., Frenkel B., Coetzee G.A. Androgen receptor-mediated repression of novel target genes. Prostate 2007, 67:1371-1383.
152. Rathkopf D., Liu G., Carducci M.A., Eisenberger M.A., Anand A., Morris M.J., Slovin S.F., Sasaki Y., Takahashi S., Ozono S., et al. Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clin. Cancer Res. 2011, 17:880-887.
153. Roell D., Baniahmad A. The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth. Mol. Cell. Endocrinol. 2011, 332:1-8.
154. Rosenfeld M.G., Lunyak V.V., Glass C.K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 2006, 20:1405-1428.
155. Sadar M.D. Small molecule inhibitors targeting the " achilles' heel" of androgen receptor activity. Cancer Res. 2011, 71:1208-1213.
156. Sadar M.D., Williams D.E., Mawji N.R., Patrick B.O., Wikanta T., Chasanah E., Irianto H.E., Soest R.V., Andersen R.J. Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells. Org. Lett. 2008, 10:4947-4950.
157. Saha L., Kaur S., Saha P.K. Pharmacotherapy of polycystic ovary syndrome - an update. Fundam. Clin. Pharmacol 2011, 10.1111/j.1472-8206.2010.00916.x.
158. Salem M., Garcia J.A. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer. Curr. Oncol. Rep. 2011, 13:92-96.
159. Salvati M.E., Balog A., Shan W., Rampulla R., Giese S., Mitt T., Furch J.A., Vite G.D., Attar R.M., Jure-Kunkel M., et al. Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists. Bioorg. Med. Chem. Lett. 2008, 18:1910-1915.
160. Sarker D., Reid A.H., Yap T.A., de Bono J.S. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin. Cancer Res. 2009, 15:4799-4805.
161. Schally A.V. Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art. BJU Int. 2007, 100(Suppl. 2):2-4.
162. Scher H.I., Beer T.M., Higano C.S., Anand A., Taplin M.E., Efstathiou E., Rathkopf D., Shelkey J., Yu E.Y., Alumkal J., et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375:1437-1446.
163. Scher H.I., Buchanan G., Gerald W., Butler L.M., Tilley W.D. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr. Relat. Cancer 2004, 11:459-476.
164. Schleich S., Papaioannou M., Baniahmad A., Matusch R. Activity-guided isolation of an antiandrogenic compound of Pygeum africanum. Planta Med. 2006, 72:547-551.
165. Schleich S., Papaioannou M., Baniahmad A., Matusch R. Extracts from Pygeum africanum and other ethnobotanical species with antiandrogenic activity. Planta Med. 2006, 72:807-813.
166. Schmidt A., Kimmel D.B., Bai C., Scafonas A., Rutledge S., Vogel R.L., McElwee-Witmer S., Chen F., Nantermet P.V., Kasparcova V., et al. Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J. Biol. Chem. 2010, 285:17054-17064.
167. Shaffer P.L., Jivan A., Dollins D.E., Claessens F., Gewirth D.T. Structural basis of androgen receptor binding to selective androgen response elements. Proc. Natl. Acad. Sci. USA 2004, 101:4758-4763.
168. Shen M.M., Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010, 24:1967-2000.
169. Stanworth R.D., Jones T.H. Testosterone for the aging male; current evidence and recommended practice. Clin. Interv. Aging 2008, 3:25-44.
170. Steinkamp M.P., O'Mahony O.A., Brogley M., Rehman H., Lapensee E.W., Dhanasekaran S., Hofer M.D., Kuefer R., Chinnaiyan A., Rubin M.A., et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res. 2009, 69:4434-4442.
171. Sun C., Robl J.A., Wang T.C., Huang Y., Kuhns J.E., Lupisella J.A., Beehler B.C., Golla R., Sleph P.G., Seethala R., et al. Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold. J. Med. Chem. 2006, 49:7596-7599.
172. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Theodore C., James N.D., Turesson I., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004, 351:1502-1512.
173. Taplin M.E., Rajeshkumar B., Halabi S., Werner C.P., Woda B.A., Picus J., Stadler W., Hayes D.F., Kantoff P.W., Vogelzang N.J., Small E.J. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J. Clin. Oncol. 2003, 21:2673-2678.
174. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., Arora V.K., Kaushik P., Cerami E., Reva B., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
175. Taylor R.A., Risbridger G.P. Prostatic tumor stroma: a key player in cancer progression. Curr. Cancer Drug Targets 2008, 8:490-497.
176. Thevis M., Gerace E., Thomas A., Beuck S., Geyer H., Schlorer N., Kearbey J.D., Dalton J.T., Schanzer W. Characterization of in vitro generated metabolites of the selective androgen receptor modulators S-22 and S-23 and in vivo comparison to post-administration canine urine specimens. Drug Test Anal. 2010, 2:589-598.
177. Toth-Fejel S., Cheek J., Calhoun K., Muller P., Pommier R.F. Estrogen and androgen receptors as comediators of breast cancer cell proliferation: providing a new therapeutic tool. Arch. Surg. 2004, 139:50-54.
178. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., Wongvipat J., Smith-Jones P.M., Yoo D., Kwon A., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
179. Trapman J., Klaassen P., Kuiper G.G., van der Korput J.A., Faber P.W., van Rooij H.C., Geurts van Kessel A., Voorhorst M.M., Mulder E., Brinkmann A.O. Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem. Biophys. Res. Commun. 1988, 153:241-248.
180. Trotter K.W., Archer T.K. Nuclear receptors and chromatin remodeling machinery. Mol. Cell. Endocrinol. 2007, 265-266:162-167.
181. Vajda E.G., Lopez F.J., Rix P., Hill R., Chen Y., Lee K.J., O'Brien Z., Chang W.Y., Meglasson M.D., Lee Y.H. Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quin olin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator. J. Pharmacol. Exp. Ther. 2009, 328:663-670.
182. Verrijdt G., Tanner T., Moehren U., Callewaert L., Haelens A., Claessens F. The androgen receptor DNA-binding domain determines androgen selectivity of transcriptional response. Biochem. Soc. Trans. 2006, 34:1089-1094.
183. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinanen R., Palmberg C., Palotie A., Tammela T., Isola J., Kallioniemi O.P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 1995, 9:401-406.
184. Waltering K.K., Helenius M.A., Sahu B., Manni V., Linja M.J., Janne O.A., Visakorpi T. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res. 2009, 69:8141-8149.
185. Wang C., Nieschlag E., Swerdloff R., Behre H.M., Hellstrom W.J., Gooren L.J., Kaufman J.M., Legros J.J., Lunenfeld B., Morales A., et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int. J. Impot. Res. 2009, 21:1-8.
186. Wang C., Nieschlag E., Swerdloff R.S., Behre H., Hellstrom W.J., Gooren L.J., Kaufman J.M., Legros J.J., Lunenfeld B., Morales A., et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009, 12:5-12.
187. Wang F., Liu X.Q., Li H., Liang K.N., Miner J.N., Hong M., Kallel E.A., van Oeveren A., Zhi L., Jiang T. Structure of the ligand-binding domain (LBD) of human androgen receptor in complex with a selective modulator LGD2226. Acta Crystallogr. F. Struct. Biol. Cryst. Commun. 2006, 62:1067-1071.
188. Wang Q., Li W., Liu X.S., Carroll J.S., Janne O.A., Keeton E.K., Chinnaiyan A.M., Pienta K.J., Brown M. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell 2007, 27:380-392.
189. Wang Q., Li W., Zhang Y., Yuan X., Xu K., Yu J., Chen Z., Beroukhim R., Wang H., Lupien M., et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009, 138:245-256.
190. Weiss B., Faus H., Haendler B. Phylogenetic conservation of the androgen receptor AR45 variant form in placental mammals. Gene 2007, 399:105-111.
191. Wierman M.E. Sex steroid effects at target tissues: mechanisms of action. Adv. Physiol. Educ. 2007, 31:26-33.
192. Wirth M.P., Hakenberg O.W., Froehner M. Adjuvant hormonal treatment - the bicalutamide early prostate cancer program. Front. Radiat. Ther. Oncol. 2008, 41:39-48.
193. Wu Z.Y., Chen K., Haendler B., McDonald T.V., Bian J.S. Stimulation of N-terminal truncated isoform of androgen receptor stabilizes human ether-a-go-go-related gene-encoded potassium channel protein via activation of extracellular signal regulated kinase 1/2. Endocrinology 2008, 149:5061-5069.
194. York B., O'Malley B.W. Steroid receptor coactivator (SRC) family: masters of systems biology. J. Biol. Chem. 2010, 285:38743-38750.
195. Yoshino H., Sato H., Shiraishi T., Tachibana K., Emura T., Honma A., Ishikura N., Tsunenari T., Watanabe M., Nishimoto A., et al. Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer. Bioorg. Med. Chem. 2010, 18:8150-8157.
196. Zhou J., Geng G., Wu J.H. Synthesis and in vitro characterization of ionone-based chalcones as novel antiandrogens effective against multiple clinically relevant androgen receptor mutants. Invest. New Drugs 2010, 28:291-298.
197. Zhou X.E., Suino-Powell K., Ludidi P.L., McDonnell D.P., Xu H.E. Expression, purification and primary crystallographic study of human androgen receptor in complex with DNA and coactivator motifs. Protein Expr. Purif. 2010, 71:21-27.
198. Zilbermint M.F., Dobs A.S. Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia. Future Oncol. 2009, 5:1211-1220.
199. Zitzmann M., Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. Int. J. Androl. 2003, 26:76-83.